AcuraStem

AcuraStem, founded in 2016 and based in Pasadena, CA, is a private, pre-clinical biotech developing disease-modifying therapies for neurodegenerative diseases like ALS and FTD. Its core innovation is the iNeuroRx® platform, which utilizes patient-derived cellular models to identify and validate novel therapeutic targets, aiming to overcome the high failure rates of traditional animal models. The company has built a pipeline targeting mechanisms like PIKFYVE and SYF2 and is led by a team with expertise in neuroscience, stem cell biology, and drug development. AcuraStem is currently pre-revenue and funded by grants and venture capital.

iNeuroRx® - A patient-based disease-modeling platform using patient-derived induced pluripotent stem cells (iPSCs) to create neuronal models that recapitulate human neurodegenerative disease processes. It is used for target discovery, validation, and therapeutic testing, with a focus on sporadic ALS and FTD.

AcuraStem competes in the crowded ALS/FTD therapeutic space with companies like Biogen, Amylyx, and many biotechs. Its key differentiation is its patient-based, human cellular platform focused on sporadic disease, contrasting with many competitors who target rare genetic forms or rely on traditional animal models.